Syed Mahmood, MD
Medical Oncology · Hagerstown, MDNPI 1942521216
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Astellas Pharma US Inc at 44.5% of the total. Reporting peaked in 2020 at $3,076 and has fallen 65.8% since, to $1,052 in 2025. That places this record below the midpoint for medical oncology clinicians in MD, where the typical reported total is $4,199.
Across 79 payments — averaging $70.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$2K
- AstraZeneca$1K
- Intuitive Surgical$295
- Novartis$251
- Pfizer$212
- AbbVie$161
- plus $1K from 18 others
Across 11 payments — averaging $742.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$3K
- E.r. Squibb & Sons, L.L.C.$3K
- AbbVie$1K
- AstraZeneca$662
What the payments were for
- Consulting fees$2,93153%
- Speaking & faculty fees$2004%
- Travel & lodging$2955%
- Food & beverage$2,03337%
- Education$1032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 3 | $2,472 |
| AstraZeneca(2 entities) | 14 | $1,113 |
| Intuitive Surgical | 2 | $295 |
| Novartis | 10 | $251 |
| Pfizer | 8 | $212 |
| AbbVie | 5 | $161 |
| Merck | 4 | $108 |
| Bristol Myers Squibb | 3 | $108 |
| Johnson & Johnson | 2 | $101 |
| Tempus AI, Inc | 1 | $92 |
| Foundation Medicine, Inc. | 3 | $87 |
| Beigene USA, Inc. | 4 | $86 |
| Karyopharm Therapeutics Inc. | 3 | $80 |
| E.r. Squibb & Sons, L.L.C. | 3 | $66 |
| Gilead | 3 | $60 |
| Daiichi Sankyo Inc. | 2 | $56 |
| Eisai Inc. | 2 | $49 |
| AVEO Pharmaceuticals, Inc. | 1 | $41 |
| GSK | 1 | $32 |
| Beone Medicines USA, Inc. | 1 | $23 |
| Incyte Corporation | 1 | $20 |
| Seagen Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Fortovia Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XOSPATA$2,430
- CALQUENCE$501
- Da Vinci Surgical System$289
How this compares
$5,562 in reported general payments places this provider in the 50th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 31 | $642,686 |
| TagrissoOsimertinib Mesylate | 32 | $567,598 |
| JakafiRuxolitinib Phosphate | 22 | $370,867 |
| BrukinsaZanubrutinib | 29 | $332,864 |
| VonjoPacritinib Citrate | 12 | $323,011 |
| Lenalidomide | 18 | $269,288 |
| PomalystPomalidomide | 12 | $261,768 |
| LonsurfTrifluridine/Tipiracil Hcl | 17 | $207,765 |
| CalquenceAcalabrutinib Maleate | 11 | $168,880 |
| XtandiEnzalutamide | 11 | $155,795 |
| Abiraterone Acetate | 37 | $148,738 |
| EliquisApixaban | 100 | $73,608 |
| OrgovyxRelugolix | 25 | $67,978 |
| Imatinib Mesylate | 20 | $24,000 |
| Acyclovir | 108 | $1,473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $1,113 | $736,47843 claims |
| Bristol Myers SquibbRevlimid | $108 | $642,68631 claims |
| Incyte CorporationJakafi | $20 | $370,86722 claims |
| Beigene USA, Inc.Brukinsa | $86 | $332,86429 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $66 | $261,76812 claims |
| Astellas Pharma US IncXtandi | $2,472 | $155,79511 claims |
| PfizerEliquis | $212 | $73,608100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 180 medical oncology providers in Maryland.
Other medical oncology in Hagerstown
- Mario EisenbergerBaltimore$2.9M
- Adrian SenderowiczBethesda$1.6M
- Mohit NarangOwing Mills$1.3M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.